Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

Endometrial ablation; less is more? Historical cohort study comparing long-term outcomes from two time periods and two treatment modalities for 854 women.

Helleland L, Bergesen LF, Rinnan KJ, Engelsen IB, Hordnes K, Trovik J.

PLoS One. 2019 Jul 10;14(7):e0219294. doi: 10.1371/journal.pone.0219294. eCollection 2019.

PMID:
31291298
Free Article
2.

Antiemetics in hyperemesis gravidarum: unawareness or negligence?

Trovik J, Vikanes AV.

BJOG. 2019 May 24. doi: 10.1111/1471-0528.15824. [Epub ahead of print] No abstract available.

PMID:
31127655
3.

Addition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: an ENITEC collaboration study.

Visser NCM, van der Putten LJM, van Egerschot A, Van de Vijver KK, Santacana M, Bronsert P, Hirschfeld M, Colas E, Gil-Moreno A, Garcia A, Mancebo G, Alameda F, Krakstad C, Tangen IL, Huvila J, Schrauwen S, Koskas M, Walker F, Weinberger V, Minar L, Hausnerova J, Snijders MPLM, van den Berg-van Erp S, Matias-Guiu X, Trovik J, Amant F, Massuger LFAG, Bulten J, Pijnenborg JMA.

Hum Pathol. 2019 May 2. pii: S0046-8177(19)30079-6. doi: 10.1016/j.humpath.2019.04.014. [Epub ahead of print]

PMID:
31054899
4.

Poor outcome in hypoxic endometrial carcinoma is related to vascular density.

Reijnen C, van Weelden WJ, Arts MSJP, Peters JP, Rijken PF, van de Vijver K, Santacana M, Bronsert P, Bulten J, Hirschfeld M, Colas E, Gil-Moreno A, Reques A, Mancebo G, Krakstad C, Trovik J, Haldorsen IS, Huvila J, Koskas M, Weinberger V, Minar L, Jandakova E, Snijders MPLM, van den Berg-van Erp S, Küsters-Vandevelde HVN, Matias-Guiu X, Amant F; ENITEC-consortium, Massuger LFAG, Bussink J, Pijnenborg JMA.

Br J Cancer. 2019 May;120(11):1037-1044. doi: 10.1038/s41416-019-0461-2. Epub 2019 Apr 23.

PMID:
31011231
5.

Incidence of gynecological fistula and its surgical treatment: A national registry-based study.

Børseth KF, Acharya G, Kiserud T, Trovik J.

Acta Obstet Gynecol Scand. 2019 Mar 19. doi: 10.1111/aogs.13611. [Epub ahead of print]

PMID:
30891735
6.

Plasma growth differentiation factor-15 is an independent marker for aggressive disease in endometrial cancer.

Engerud H, Hope K, Berg HF, Fasmer KE, Tangen IL, Haldorsen IS, Trovik J, Krakstad C.

PLoS One. 2019 Jan 15;14(1):e0210585. doi: 10.1371/journal.pone.0210585. eCollection 2019.

7.

Blood steroids are associated with prognosis and fat distribution in endometrial cancer.

Tangen IL, Fasmer KE, Konings GF, Jochems A, Delvoux B, Xanthoulea S, Stokowy T, Strand E, Berg HF, Auriola S, Trovik J, Häkkinen MR, Haldorsen IS; ENITEC. Electronic address: https://www.esgo.org, Krakstad C, Romano A.

Gynecol Oncol. 2019 Jan;152(1):46-52. doi: 10.1016/j.ygyno.2018.10.024. Epub 2018 Oct 26.

PMID:
30554934
8.

PIK3CA Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma.

Holst F, Werner HMJ, Mjøs S, Hoivik EA, Kusonmano K, Wik E, Berg A, Birkeland E, Gibson WJ, Halle MK, Trovik J, Cherniack AD, Kalland KH, Mills GB, Singer CF, Krakstad C, Beroukhim R, Salvesen HB.

Clin Cancer Res. 2019 Jan 1;25(1):334-345. doi: 10.1158/1078-0432.CCR-18-0452. Epub 2018 Nov 15.

9.

Identification of highly connected and differentially expressed gene subnetworks in metastasizing endometrial cancer.

Kusonmano K, Halle MK, Wik E, Hoivik EA, Krakstad C, Mauland KK, Tangen IL, Berg A, Werner HMJ, Trovik J, Øyan AM, Kalland KH, Jonassen I, Salvesen HB, Petersen K.

PLoS One. 2018 Nov 1;13(11):e0206665. doi: 10.1371/journal.pone.0206665. eCollection 2018.

10.

Preoperative tumor texture analysis on MRI predicts high-risk disease and reduced survival in endometrial cancer.

Ytre-Hauge S, Dybvik JA, Lundervold A, Salvesen ØO, Krakstad C, Fasmer KE, Werner HM, Ganeshan B, Høivik E, Bjørge L, Trovik J, Haldorsen IS.

J Magn Reson Imaging. 2018 Dec;48(6):1637-1647. doi: 10.1002/jmri.26184. Epub 2018 Aug 13.

PMID:
30102441
11.

Identification of nine new susceptibility loci for endometrial cancer.

O'Mara TA, Glubb DM, Amant F, Annibali D, Ashton K, Attia J, Auer PL, Beckmann MW, Black A, Bolla MK, Brauch H, Brenner H, Brinton L, Buchanan DD, Burwinkel B, Chang-Claude J, Chanock SJ, Chen C, Chen MM, Cheng THT, Clarke CL, Clendenning M, Cook LS, Couch FJ, Cox A, Crous-Bous M, Czene K, Day F, Dennis J, Depreeuw J, Doherty JA, Dörk T, Dowdy SC, Dürst M, Ekici AB, Fasching PA, Fridley BL, Friedenreich CM, Fritschi L, Fung J, García-Closas M, Gaudet MM, Giles GG, Goode EL, Gorman M, Haiman CA, Hall P, Hankison SE, Healey CS, Hein A, Hillemanns P, Hodgson S, Hoivik EA, Holliday EG, Hopper JL, Hunter DJ, Jones A, Krakstad C, Kristensen VN, Lambrechts D, Marchand LL, Liang X, Lindblom A, Lissowska J, Long J, Lu L, Magliocco AM, Martin L, McEvoy M, Meindl A, Michailidou K, Milne RL, Mints M, Montgomery GW, Nassir R, Olsson H, Orlow I, Otton G, Palles C, Perry JRB, Peto J, Pooler L, Prescott J, Proietto T, Rebbeck TR, Risch HA, Rogers PAW, Rübner M, Runnebaum I, Sacerdote C, Sarto GE, Schumacher F, Scott RJ, Setiawan VW, Shah M, Sheng X, Shu XO, Southey MC, Swerdlow AJ, Tham E, Trovik J, Turman C, Tyrer JP, Vachon C, VanDen Berg D, Vanderstichele A, Wang Z, Webb PM, Wentzensen N, Werner HMJ, Winham SJ, Wolk A, Xia L, Xiang YB, Yang HP, Yu H, Zheng W, Pharoah PDP, Dunning AM, Kraft P, De Vivo I, Tomlinson I, Easton DF, Spurdle AB, Thompson DJ.

Nat Commun. 2018 Aug 9;9(1):3166. doi: 10.1038/s41467-018-05427-7.

12.

Asparaginase-like protein 1 expression in curettage independently predicts lymph node metastasis in endometrial carcinoma: a multicentre study.

Fonnes T, Trovik J, Edqvist PH, Fasmer KE, Marcickiewicz J, Tingulstad S, Staff AC, Bjørge L, Amant F, Haldorsen IS, Werner H, Akslen LA, Tangen IL, Krakstad C.

BJOG. 2018 Dec;125(13):1695-1703. doi: 10.1111/1471-0528.15403. Epub 2018 Aug 19.

PMID:
29989298
13.

High expression of the p53 isoform γ is associated with reduced progression-free survival in uterine serous carcinoma.

Bischof K, Knappskog S, Stefansson I, McCormack EM, Trovik J, Werner HMJ, Woie K, Gjertsen BT, Bjorge L.

BMC Cancer. 2018 Jun 25;18(1):684. doi: 10.1186/s12885-018-4591-3.

14.

Association Between Proportion of Nuclei With High Chromatin Entropy and Prognosis in Gynecological Cancers.

Nielsen B, Kleppe A, Hveem TS, Pradhan M, Syvertsen RA, Nesheim JA, Kristensen GB, Trovik J, Kerr DJ, Albregtsen F, Danielsen HE.

J Natl Cancer Inst. 2018 Dec 1;110(12):1400-1408. doi: 10.1093/jnci/djy063.

15.

Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses.

Painter JN, O'Mara TA, Morris AP, Cheng THT, Gorman M, Martin L, Hodson S, Jones A, Martin NG, Gordon S, Henders AK, Attia J, McEvoy M, Holliday EG, Scott RJ, Webb PM, Fasching PA, Beckmann MW, Ekici AB, Hein A, Rübner M, Hall P, Czene K, Dörk T, Dürst M, Hillemanns P, Runnebaum I, Lambrechts D, Amant F, Annibali D, Depreeuw J, Vanderstichele A, Goode EL, Cunningham JM, Dowdy SC, Winham SJ, Trovik J, Hoivik E, Werner HMJ, Krakstad C, Ashton K, Otton G, Proietto T, Tham E, Mints M, Ahmed S, Healey CS, Shah M, Pharoah PDP, Dunning AM, Dennis J, Bolla MK, Michailidou K, Wang Q, Tyrer JP, Hopper JL, Peto J, Swerdlow AJ, Burwinkel B, Brenner H, Meindl A, Brauch H, Lindblom A, Chang-Claude J, Couch FJ, Giles GG, Kristensen VN, Cox A, Zondervan KT, Nyholt DR, MacGregor S, Montgomery GW, Tomlinson I, Easton DF, Thompson DJ, Spurdle AB.

Cancer Med. 2018 May;7(5):1978-1987. doi: 10.1002/cam4.1445. Epub 2018 Apr 2.

16.

Chromatin organisation and cancer prognosis: a pan-cancer study.

Kleppe A, Albregtsen F, Vlatkovic L, Pradhan M, Nielsen B, Hveem TS, Askautrud HA, Kristensen GB, Nesbakken A, Trovik J, Wæhre H, Tomlinson I, Shepherd NA, Novelli M, Kerr DJ, Danielsen HE.

Lancet Oncol. 2018 Mar;19(3):356-369. doi: 10.1016/S1470-2045(17)30899-9. Epub 2018 Feb 3.

17.

Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study.

van der Putten LJM, Visser NCM, van de Vijver K, Santacana M, Bronsert P, Bulten J, Hirschfeld M, Colas E, Gil-Moreno A, Garcia A, Mancebo G, Alameda F, Trovik J, Kopperud RK, Huvila J, Schrauwen S, Koskas M, Walker F, Weinberger V, Minar L, Jandakova E, Snijders MPLM, van den Berg-van Erp S, Matias-Guiu X, Salvesen HB, Werner HMJ, Amant F, Massuger LFAG, Pijnenborg JMA.

Int J Gynecol Cancer. 2018 Mar;28(3):514-523. doi: 10.1097/IGC.0000000000001187.

PMID:
29324536
18.

Tumour-microenvironmental blood flow determines a metabolomic signature identifying lysophospholipids and resolvin D as biomarkers in endometrial cancer patients.

Eritja N, Jové M, Fasmer KE, Gatius S, Portero-Otin M, Trovik J, Krakstad C, Sol J, Pamplona R, Haldorsen IS, Matias-Guiu X.

Oncotarget. 2017 Nov 20;8(65):109018-109026. doi: 10.18632/oncotarget.22558. eCollection 2017 Dec 12.

19.

Proteomic profiling of endometrioid endometrial cancer reveals differential expression of hormone receptors and MAPK signaling proteins in obese versus non-obese patients.

Mauland KK, Ju Z, Tangen IL, Berg A, Kalland KH, Øyan AM, Bjørge L, Westin SN, Krakstad C, Trovik J, Mills GB, Hoivik EA, Johanna Werner HM.

Oncotarget. 2017 Oct 31;8(63):106989-107001. doi: 10.18632/oncotarget.22203. eCollection 2017 Dec 5.

20.

Adverse Maternal and Birth Outcomes in Women Hospitalised due to Hyperemesis gravidarum.

Vikanes Å, Trovik J.

Paediatr Perinat Epidemiol. 2018 Jan;32(1):52-54. doi: 10.1111/ppe.12438. Epub 2017 Dec 29. No abstract available.

PMID:
29286189
21.

High visceral fat percentage is associated with poor outcome in endometrial cancer.

Mauland KK, Eng Ø, Ytre-Hauge S, Tangen IL, Berg A, Salvesen HB, Salvesen ØO, Krakstad C, Trovik J, Hoivik EA, Werner HMJ, Mellgren G, Haldorsen IS.

Oncotarget. 2017 Oct 19;8(62):105184-105195. doi: 10.18632/oncotarget.21917. eCollection 2017 Dec 1.

22.

HER2 expression patterns in paired primary and metastatic endometrial cancer lesions.

Halle MK, Tangen IL, Berg HF, Hoivik EA, Mauland KK, Kusonmano K, Berg A, Hurtado A, Kalland KH, Øyan AM, Stefansson I, Vintermyr OK, Werner HM, Haldorsen IS, Trovik J, Salvesen HB, Krakstad C.

Br J Cancer. 2018 Feb 6;118(3):378-387. doi: 10.1038/bjc.2017.422. Epub 2017 Nov 23.

23.

Preoperative quantitative dynamic contrast-enhanced MRI and diffusion-weighted imaging predict aggressive disease in endometrial cancer.

Fasmer KE, Bjørnerud A, Ytre-Hauge S, Grüner R, Tangen IL, Werner HM, Bjørge L, Salvesen ØO, Trovik J, Krakstad C, Haldorsen IS.

Acta Radiol. 2018 Aug;59(8):1010-1017. doi: 10.1177/0284185117740932. Epub 2017 Nov 14.

PMID:
29137496
24.

Long non-coding RNA HAND2-AS1 inhibits invasion and metastasis in endometrioid endometrial carcinoma through inactivating neuromedin U.

Yang X, Wang CC, Lee WYW, Trovik J, Chung TKH, Kwong J.

Cancer Lett. 2018 Jan 28;413:23-34. doi: 10.1016/j.canlet.2017.10.028. Epub 2017 Oct 26.

PMID:
29107108
25.

Asparaginase-like protein 1 is an independent prognostic marker in primary endometrial cancer, and is frequently lost in metastatic lesions.

Fonnes T, Berg HF, Bredholt T, Edqvist PD, Sortland K, Berg A, Salvesen HB, Akslen LA, Werner HMJ, Trovik J, Tangen IL, Krakstad C.

Gynecol Oncol. 2018 Jan;148(1):197-203. doi: 10.1016/j.ygyno.2017.10.025. Epub 2017 Oct 31.

PMID:
29096882
26.

Preoperative imaging markers and PDZ-binding kinase tissue expression predict low-risk disease in endometrial hyperplasias and low grade cancers.

Berg A, Gulati A, Ytre-Hauge S, Fasmer KE, Mauland KK, Hoivik EA, Husby JA, Tangen IL, Trovik J, Halle MK, Stefansson I, Akslen LA, Woie K, Bjørge L, Salvesen HB, Salvesen ØO, Werner HMJ, Haldorsen IS, Krakstad C.

Oncotarget. 2017 Jul 31;8(40):68530-68541. doi: 10.18632/oncotarget.19708. eCollection 2017 Sep 15.

27.

Type of vascular invasion in association with progress of endometrial cancer.

Visser NCM, Werner HMJ, Krakstad C, Mauland KK, Trovik J, Massuger LFAG, Nagtegaal ID, Pijnenborg JMA, Salvesen HB, Bulten J, Stefansson IM.

APMIS. 2017 Dec;125(12):1084-1091. doi: 10.1111/apm.12774. Epub 2017 Oct 4.

PMID:
28975668
28.

Expression of glucocorticoid receptor is associated with aggressive primary endometrial cancer and increases from primary to metastatic lesions.

Tangen IL, Veneris JT, Halle MK, Werner HM, Trovik J, Akslen LA, Salvesen HB, Conzen SD, Fleming GF, Krakstad C.

Gynecol Oncol. 2017 Dec;147(3):672-677. doi: 10.1016/j.ygyno.2017.09.013. Epub 2017 Sep 18.

PMID:
28927900
29.

In vivo MR spectroscopy predicts high tumor grade in endometrial cancer.

Ytre-Hauge S, Esmaeili M, Sjøbakk TE, Grüner R, Woie K, Werner HM, Krakstad C, Bjørge L, Salvesen ØO, Stefansson IM, Trovik J, Bathen TF, Haldorsen IS.

Acta Radiol. 2018 Apr;59(4):497-505. doi: 10.1177/0284185117733297. Epub 2017 Sep 19.

PMID:
28927296
30.

PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer.

Mjos S, Werner HMJ, Birkeland E, Holst F, Berg A, Halle MK, Tangen IL, Kusonmano K, Mauland KK, Oyan AM, Kalland KH, Lewis AE, Mills GB, Krakstad C, Trovik J, Salvesen HB, Hoivik EA.

Sci Rep. 2017 Aug 31;7(1):10240. doi: 10.1038/s41598-017-10717-z.

31.

Late-week surgical treatment of endometrial cancer is associated with worse long-term outcome: Results from a prospective, multicenter study.

Njølstad TS, Werner HM, Marcickiewicz J, Tingulstad S, Staff AC, Oddenes K, Bjørge L, Engh ME, Woie K, Tjugum J, Lode MS, Amant F, Salvesen HB, Trovik J.

PLoS One. 2017 Aug 3;12(8):e0182223. doi: 10.1371/journal.pone.0182223. eCollection 2017.

32.

Expression of L1CAM in curettage or high L1CAM level in preoperative blood samples predicts lymph node metastases and poor outcome in endometrial cancer patients.

Tangen IL, Kopperud RK, Visser NC, Staff AC, Tingulstad S, Marcickiewicz J, Amant F, Bjørge L, Pijnenborg JM, Salvesen HB, Werner HM, Trovik J, Krakstad C.

Br J Cancer. 2017 Sep 5;117(6):840-847. doi: 10.1038/bjc.2017.235. Epub 2017 Jul 27.

33.

Corrigendum: Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth.

Holst F, Hoivik EA, Gibson WJ, Taylor-Weiner A, Schumacher SE, Asmann YW, Grossmann P, Trovik J, Necela BM, Thompson EA, Meyerson M, Beroukhim R, Salvesen HB, Cherniack AD.

Sci Rep. 2017 Jun 30;7:46873. doi: 10.1038/srep46873.

34.

Clinicopathologic and molecular markers in cervical carcinoma: a prospective cohort study.

Halle MK, Ojesina AI, Engerud H, Woie K, Tangen IL, Holst F, Høivik E, Kusonmano K, Haldorsen IS, Vintermyr OK, Trovik J, Bertelsen BI, Salvesen HB, Krakstad C.

Am J Obstet Gynecol. 2017 Oct;217(4):432.e1-432.e17. doi: 10.1016/j.ajog.2017.05.068. Epub 2017 Jun 24.

PMID:
28599900
35.

Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas-an ENITEC Group Initiative.

Cuppens T, Annibali D, Coosemans A, Trovik J, Ter Haar N, Colas E, Garcia-Jimenez A, Van de Vijver K, Kruitwagen RP, Brinkhuis M, Zikan M, Dundr P, Huvila J, Carpén O, Haybaeck J, Moinfar F, Salvesen HB, Stukan M, Mestdagh C, Zweemer RP, Massuger LF, Mallmann MR, Wardelmann E, Mints M, Verbist G, Thomas D, Gommé E, Hermans E, Moerman P, Bosse T, Amant F.

Clin Cancer Res. 2017 Mar 1;23(5):1274-1285. doi: 10.1158/1078-0432.CCR-16-2149.

36.

Aneuploidy related transcriptional changes in endometrial cancer link low expression of chromosome 15q genes to poor survival.

Mauland KK, Wik E, Hoivik EA, Kusonmano K, Halle MK, Berg A, Haugland HK, Øyan AM, Kalland KH, Stefansson IM, Akslen LA, Krakstad C, Trovik J, Werner HM, Salvesen HB.

Oncotarget. 2017 Feb 7;8(6):9696-9707. doi: 10.18632/oncotarget.14201.

37.

Genetic Risk Score Mendelian Randomization Shows that Obesity Measured as Body Mass Index, but not Waist:Hip Ratio, Is Causal for Endometrial Cancer.

Painter JN, O'Mara TA, Marquart L, Webb PM, Attia J, Medland SE, Cheng T, Dennis J, Holliday EG, McEvoy M, Scott RJ, Ahmed S, Healey CS, Shah M, Gorman M, Martin L, Hodgson SV, Beckmann MW, Ekici AB, Fasching PA, Hein A, Rübner M, Czene K, Darabi H, Hall P, Li J, Dörk T, Dürst M, Hillemanns P, Runnebaum IB, Amant F, Annibali D, Depreeuw J, Lambrechts D, Neven P, Cunningham JM, Dowdy SC, Goode EL, Fridley BL, Winham SJ, Njølstad TS, Salvesen HB, Trovik J, Werner HM, Ashton KA, Otton G, Proietto A, Mints M, Tham E, Bolla MK, Michailidou K, Wang Q, Tyrer JP, Hopper JL, Peto J, Swerdlow AJ, Burwinkel B, Brenner H, Meindl A, Brauch H, Lindblom A, Chang-Claude J, Couch FJ, Giles GG, Kristensen VN, Cox A, Pharoah PD, Tomlinson I, Dunning AM, Easton DF, Thompson DJ, Spurdle AB; AOCS Group; for RENDOCAS; National Study of Endometrial Cancer Genetics Group (NSECG); Australian National Endometrial Cancer Study Group (ANECS).

Cancer Epidemiol Biomarkers Prev. 2016 Nov;25(11):1503-1510. Epub 2016 Aug 22.

38.
39.

Tissue and imaging biomarkers for hypoxia predict poor outcome in endometrial cancer.

Berg A, Fasmer KE, Mauland KK, Ytre-Hauge S, Hoivik EA, Husby JA, Tangen IL, Trovik J, Halle MK, Woie K, Bjørge L, Bjørnerud A, Salvesen HB, Werner HM, Krakstad C, Haldorsen IS.

Oncotarget. 2016 Oct 25;7(43):69844-69856. doi: 10.18632/oncotarget.12004.

40.

Changes in Chromatin Structure in Curettage Specimens Identifies High-Risk Patients in Endometrial Cancer.

Hveem TS, Njølstad TS, Nielsen B, Syvertsen RA, Nesheim JA, Kjæreng ML, Kildal W, Pradhan M, Marcickiewicz J, Tingulstad S, Staff AC, Haugland HK, Eraker R, Oddenes K, Rokne JA, Tjugum J, Lode MS, Amant F, Werner HM, Bjørge L, Albregtsen F, Liestøl K, Salvesen HB, Trovik J, Danielsen HE; ENITEC network/MoMaTEC study group.

Cancer Epidemiol Biomarkers Prev. 2017 Jan;26(1):61-67. doi: 10.1158/1055-9965.EPI-16-0215. Epub 2016 Sep 1.

41.

L1CAM expression in endometrial carcinomas: an ENITEC collaboration study.

van der Putten LJ, Visser NC, van de Vijver K, Santacana M, Bronsert P, Bulten J, Hirschfeld M, Colas E, Gil-Moreno A, Garcia A, Mancebo G, Alameda F, Trovik J, Kopperud RK, Huvila J, Schrauwen S, Koskas M, Walker F, Weinberger V, Minar L, Jandakova E, Snijders MP, van den Berg-van Erp S, Matias-Guiu X, Salvesen HB, Amant F, Massuger LF, Pijnenborg JM.

Br J Cancer. 2016 Sep 6;115(6):716-24. doi: 10.1038/bjc.2016.235. Epub 2016 Aug 9.

42.

Androgen receptor as potential therapeutic target in metastatic endometrial cancer.

Tangen IL, Onyango TB, Kopperud R, Berg A, Halle MK, Øyan AM, Werner HM, Trovik J, Kalland KH, Salvesen HB, Krakstad C.

Oncotarget. 2016 Aug 2;7(31):49289-49298. doi: 10.18632/oncotarget.10334.

43.

The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis.

Gibson WJ, Hoivik EA, Halle MK, Taylor-Weiner A, Cherniack AD, Berg A, Holst F, Zack TI, Werner HM, Staby KM, Rosenberg M, Stefansson IM, Kusonmano K, Chevalier A, Mauland KK, Trovik J, Krakstad C, Giannakis M, Hodis E, Woie K, Bjorge L, Vintermyr OK, Wala JA, Lawrence MS, Getz G, Carter SL, Beroukhim R, Salvesen HB.

Nat Genet. 2016 Aug;48(8):848-55. doi: 10.1038/ng.3602. Epub 2016 Jun 27.

44.

Corrigendum: Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth.

Holst F, Hoivik EA, Gibson WJ, Taylor-Weiner A, Schumacher SE, Asmann YW, Grossmann P, Trovik J, Necela BM, Thompson EA, Meyerson M, Beroukhim R, Salvesen HB, Cherniack AD.

Sci Rep. 2016 Jun 24;6:27960. doi: 10.1038/srep27960. No abstract available.

45.

Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth.

Holst F, Hoivik EA, Gibson WJ, Taylor-Weiner A, Schumacher SE, Asmann YW, Grossmann P, Trovik J, Necela BM, Thompson EA, Meyerson M, Beroukhim R, Salvesen HB, Cherniack AD.

Sci Rep. 2016 May 10;6:25521. doi: 10.1038/srep25521. Erratum in: Sci Rep. 2016 Jun 24;6:27960. Sci Rep. 2017 Jun 30;7:46873.

46.

Five endometrial cancer risk loci identified through genome-wide association analysis.

Cheng TH, Thompson DJ, O'Mara TA, Painter JN, Glubb DM, Flach S, Lewis A, French JD, Freeman-Mills L, Church D, Gorman M, Martin L; National Study of Endometrial Cancer Genetics Group (NSECG), Hodgson S, Webb PM; Australian National Endometrial Cancer Study Group (ANECS), Attia J, Holliday EG, McEvoy M, Scott RJ, Henders AK, Martin NG, Montgomery GW, Nyholt DR, Ahmed S, Healey CS, Shah M, Dennis J, Fasching PA, Beckmann MW, Hein A, Ekici AB, Hall P, Czene K, Darabi H, Li J, Dörk T, Dürst M, Hillemanns P, Runnebaum I, Amant F, Schrauwen S, Zhao H, Lambrechts D, Depreeuw J, Dowdy SC, Goode EL, Fridley BL, Winham SJ, Njølstad TS, Salvesen HB, Trovik J, Werner HM, Ashton K, Otton G, Proietto T, Liu T, Mints M, Tham E; RENDOCAS, Consortium C, Jun Li M, Yip SH, Wang J, Bolla MK, Michailidou K, Wang Q, Tyrer JP, Dunlop M, Houlston R, Palles C, Hopper JL; AOCS Group, Peto J, Swerdlow AJ, Burwinkel B, Brenner H, Meindl A, Brauch H, Lindblom A, Chang-Claude J, Couch FJ, Giles GG, Kristensen VN, Cox A, Cunningham JM, Pharoah PDP, Dunning AM, Edwards SL, Easton DF, Tomlinson I, Spurdle AB.

Nat Genet. 2016 Jun;48(6):667-674. doi: 10.1038/ng.3562. Epub 2016 May 2.

47.

Incidence of obstetric fistula in Norway: a population-based prospective cohort study.

Trovik J, Thornhill HF, Kiserud T.

Acta Obstet Gynecol Scand. 2016 Apr;95(4):405-10. doi: 10.1111/aogs.12845. Epub 2016 Jan 20.

PMID:
26713965
48.

Meta-analysis of genome-wide association studies identifies common susceptibility polymorphisms for colorectal and endometrial cancer near SH2B3 and TSHZ1.

Cheng TH, Thompson D, Painter J, O'Mara T, Gorman M, Martin L, Palles C, Jones A, Buchanan DD, Win AK, Hopper J, Jenkins M, Lindor NM, Newcomb PA, Gallinger S, Conti D, Schumacher F, Casey G, Giles GG, Pharoah P, Peto J, Cox A, Swerdlow A, Couch F, Cunningham JM, Goode EL, Winham SJ, Lambrechts D, Fasching P, Burwinkel B, Brenner H, Brauch H, Chang-Claude J, Salvesen HB, Kristensen V, Darabi H, Li J, Liu T, Lindblom A, Hall P, de Polanco ME, Sans M, Carracedo A, Castellvi-Bel S, Rojas-Martinez A, Aguiar Jnr S, Teixeira MR, Dunning AM, Dennis J, Otton G, Proietto T, Holliday E, Attia J, Ashton K, Scott RJ, McEvoy M, Dowdy SC, Fridley BL, Werner HM, Trovik J, Njolstad TS, Tham E, Mints M, Runnebaum I, Hillemanns P, Dörk T, Amant F, Schrauwen S, Hein A, Beckmann MW, Ekici A, Czene K, Meindl A, Bolla MK, Michailidou K, Tyrer JP, Wang Q, Ahmed S, Healey CS, Shah M, Annibali D, Depreeuw J, Al-Tassan NA, Harris R, Meyer BF, Whiffin N, Hosking FJ, Kinnersley B, Farrington SM, Timofeeva M, Tenesa A, Campbell H, Haile RW, Hodgson S, Carvajal-Carmona L, Cheadle JP, Easton D, Dunlop M, Houlston R, Spurdle A, Tomlinson I.

Sci Rep. 2015 Dec 1;5:17369. doi: 10.1038/srep17369.

49.

CYP19A1 fine-mapping and Mendelian randomization: estradiol is causal for endometrial cancer.

Thompson DJ, O'Mara TA, Glubb DM, Painter JN, Cheng T, Folkerd E, Doody D, Dennis J, Webb PM; Australian National Endometrial Cancer Study Group (ANECS), Gorman M, Martin L, Hodgson S; National Study of Endometrial Cancer Genetics Group (NSECG), Michailidou K, Tyrer JP, Maranian MJ, Hall P, Czene K, Darabi H, Li J, Fasching PA, Hein A, Beckmann MW, Ekici AB, Dörk T, Hillemanns P, Dürst M, Runnebaum I, Zhao H, Depreeuw J, Schrauwen S, Amant F, Goode EL, Fridley BL, Dowdy SC, Winham SJ, Salvesen HB, Trovik J, Njolstad TS, Werner HM, Ashton K, Proietto T, Otton G, Carvajal-Carmona L, Tham E, Liu T, Mints M; for RENDOCAS, Scott RJ, McEvoy M, Attia J, Holliday EG, Montgomery GW, Martin NG, Nyholt DR, Henders AK, Hopper JL, Traficante N; AOCS Group, Ruebner M, Swerdlow AJ, Burwinkel B, Brenner H, Meindl A, Brauch H, Lindblom A, Lambrechts D, Chang-Claude J, Couch FJ, Giles GG, Kristensen VN, Cox A, Bolla MK, Wang Q, Bojesen SE, Shah M, Luben R, Khaw KT, Pharoah PD, Dunning AM, Tomlinson I, Dowsett M, Easton DF, Spurdle AB.

Endocr Relat Cancer. 2016 Feb;23(2):77-91. doi: 10.1530/ERC-15-0386. Epub 2015 Nov 16.

50.

Tumor necrosis is an important hallmark of aggressive endometrial cancer and associates with hypoxia, angiogenesis and inflammation responses.

Bredholt G, Mannelqvist M, Stefansson IM, Birkeland E, Bø TH, Øyan AM, Trovik J, Kalland KH, Jonassen I, Salvesen HB, Wik E, Akslen LA.

Oncotarget. 2015 Nov 24;6(37):39676-91. doi: 10.18632/oncotarget.5344.

Supplemental Content

Loading ...
Support Center